Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Exercise, Prostate Cancer and Circulating Tumour Cells (ExPeCT)

1 mai 2018 mis à jour par: Prof Stephen Finn, University of Dublin, Trinity College

Evasion of Immune Editing by Circulating Tumour Cells in an Exercise Modifiable Mechanism Underlying Aggressive Behaviour in Obese Men With Prostate Cancer

Obesity, known to be associated with a pro-inflammatory, pro-thrombotic humoral milieu, confers a worse prognosis in prostate cancer (PrCa). Circulating tumour cells (CTCs) are identified in the blood in advanced cancer. Their quantitation provides prognostic information. "Cloaking" of CTCs by adherent platelets impedes natural killer (NK)-cell clearance of CTCs from the circulation, enhancing metastatic spread. NK-cell function in blood and in solid organs is quantitatively and qualitatively reduced in obesity. Platelet cloaking may be enhanced in obesity due to the pro-inflammatory, pro-thrombotic state, and may be a mechanism for worse cancer-specific outcomes in this group. Obesity and its biochemical effects may be influenced by lifestyle changes such as exercise. Physical activity reduces levels of systemic inflammatory mediators and so an aerobic exercise intervention may represent an accessible and cost-effective means of ameliorating the pro-inflammatory effects of obesity. The ExPeCT trial will determine if a prescribed exercise intervention can ameliorate the degree of platelet cloaking in obese and non-obese men with advanced prostate cancer.

Aperçu de l'étude

Statut

Complété

Intervention / Traitement

Description détaillée

The overarching hypothesis is that enhanced platelet cloaking of circulating tumour cells in obese men with prostate cancer, due to increased systemic inflammation, is a mechanism underlying worse prognosis of cancer in these patients.

The investigators aim to test the following four hypotheses, dividing the experimental and analytical work into four separate projects.

  1. Platelet cloaking of circulating PrCa tumour cells is more prominent in men with obesity than without
  2. Regular exercise can ameliorate platelet cloaking
  3. The degree of platelet cloaking varies with levels of systemic and primary tumour inflammation and coagulability
  4. Expression of an obesity-associated lethality gene signature leads to variation in platelet cloaking

For the first hypothesis, 200 men with metastatic PrCa will be recruited, and divided into exposed and non-exposed groups based on body mass index (BMI >25). The objective will be to enumerate CTCs and quantify the degree of platelet cloaking in exposed and non-exposed groups, and to draw meaningful comparisons between the two.

For the second hypothesis, the objective will be to determine to what extent the number of CTCs and the degree of platelet cloaking varies in exposed and non-exposed groups following a supervised exercise intervention, and to compare this with a non-exercised comparison group. The exercise intervention will prescribe moderate intensity aerobic exercise that will be supervised once per week for 3 months and completed independently at home for a further 3 months. Patients will wear Polar heart rate monitors to monitor exercise prescription and progression. Assessments including blood sampling and quality of life questionnaires will be completed at baseline, 3 months and 6 months.

For the third hypothesis, the objective will be to build a serological, haematological and immunological picture of the state of systemic inflammation and coagulability, and the degree of inflammation within the prostate gland. Furthermore, the investigators intend to correlate and compare these variables with the results of the first and second objectives, in order to determine whether the number of CTCs and the degree of platelet cloaking varies with changes in the inflammatory / coagulatory milieu.

For the fourth hypothesis, the objective will be to determine whether the expression profile of a number of lethality-associated genes, known to be associated with PrCa progression, coagulation and stem-cell like phenotype, correlates with the number of CTCs and the degree of their cloaking by platelets.

CTC numbers and the degree of platelet cloaking will be common denominators which anchor these four objectives together and enable comparison between them.

Type d'étude

Interventionnel

Inscription (Réel)

67

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Dublin, Irlande
        • Beaumont Hospital
      • Dublin, Irlande
        • Mater Misericordiae University Hospital
      • Dublin, Irlande, 8
        • St James's Hospital
      • Dublin, Irlande
        • St Luke's Hospital
    • Dublin
      • Tallaght, Dublin, Irlande, 24
        • Adelaide and Meath Incorporating the National Children's Hospital
      • London, Royaume-Uni
        • Guy's St Thomas

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Homme

La description

Inclusion Criteria:

  1. Written informed consent obtained before any study-related procedures
  2. Age ≥ 18 years and male
  3. Histologically confirmed diagnosis of prostate adenocarcinoma
  4. Metastatic disease as confirmed by CT/MRI or by bone scan
  5. Stable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections, or major surgery within 28 days prior to randomisation
  6. Capable of participating safely in the proposed exercise intervention as assessed and signed off by a treating physician involved in ExPeCT recruitment.

Exclusion Criteria:

  1. No history of radical prostatectomy
  2. No previous diagnosis of any other malignant tumour (patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded provided they have undergone complete resection)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Exercise group
6 month supervised and home based moderate intensity aerobic exercise programme
6 month supervised and home based aerobic exercise intervention
Aucune intervention: Control
Non-exercising control group receiving usual care

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in Platelet cloaking of Circulating Tumour Cells
Délai: Change from baseline in platelet cloaking of circulating tumours cells at 3 months and 6 months
Enumeration of circulating tumour cells and degree of platelet cloaking of CTCs
Change from baseline in platelet cloaking of circulating tumours cells at 3 months and 6 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in systemic inflammation
Délai: Change in cytokines from baseline in inflammation at 3 months and 6 months
Blood samples will be taken from participants at each assessment and analysed by multi-plex assays for levels of cytokines (TNF-alpha and interleukin (IL)-6
Change in cytokines from baseline in inflammation at 3 months and 6 months
Change in Quality of Life Questionnaire
Délai: Change from baseline in quality of life at 3 months and 6 months
Participants will complete quality of life questionnaires assessing a range of issues including sleep, diet quality and physical activity at each assessment
Change from baseline in quality of life at 3 months and 6 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Stephen Finn, University of Dublin, Trinity College

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 octobre 2014

Achèvement primaire (Réel)

1 juin 2017

Achèvement de l'étude (Réel)

1 juin 2017

Dates d'inscription aux études

Première soumission

12 mai 2015

Première soumission répondant aux critères de contrôle qualité

20 mai 2015

Première publication (Estimation)

25 mai 2015

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

2 mai 2018

Dernière mise à jour soumise répondant aux critères de contrôle qualité

1 mai 2018

Dernière vérification

1 mai 2018

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner